Liposomes, a promising strategy for clinical application of platinum derivatives

Expert Opinion on Drug Delivery

Volumn 10, Issue 6, 2013, Pages 829-844

  Zalba, Sara ^a   Garrido, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Clinical application; Liposomes; Platinum derivatives; Targeting

Indexed keywords

AMIKACIN; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AUSTRAGEN; AVIAN RETROVIRUS; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HEPATITIS A VACCINE; LIPOPLATIN; LIPOSOME; LIPOXAL; NAVELBINE; NOVASOME; NYSTATIN; OXALIPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM DERIVATIVE; PUMACTANT; SI 077 B103; SPI 077 B 103; TOPEX BR; UNCLASSIFIED DRUG; VENTUS; VINCAXOME;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HUMAN; LIPID COMPOSITION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; REVIEW; SENSORY NEUROPATHY; TESTIS CANCER; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS; PLATINUM COMPOUNDS;

EID: 84878024121     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.778240     Document Type: Review

References (100)

1. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63(12):1020-30
2. Gabizon AA. Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects. J Drug Target 2002;10:535-8
3. Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066(1):29-36
4. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
5. Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998;56:747-56
6. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161(2):175-87
7. Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011;8(3):683-700
8. Mamot C, Drummond DC, Hong K, et al. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003;6:271-9
9. Goren D, Horowitz AT, Tzemach D, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;5):1949-57
10. Bangham JA, Lea EJ. The interaction of detergents with bilayer lipid membranes. Biochim Biophys Acta 1978;511:388-96
11. Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 1980;9:467-508
12. Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 1995;12:229-46
13. Harper BW, Krause-Heuer AM, Grant MP, et al. Advances in platinum chemotherapeutics. Chemistry (Easton) 2010;16(24):7064-77
14. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691-707
15. Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften 1973;60:399-406
16. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008;6:1-18
17. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4
18. Lee FH, Canetta R, Issell BF, Lenaz L. New platinum complexes in clinical trials. Cancer Treat Rev 1983;10:39-51
19. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000;59:29-36
20. Burges A, Schmalfeldt B. Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int 2011;108:635-41
21. Banerjee S, Rustin G, Paul J, et al. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol 2012; Epub ahead of print
22. Voland C, Bord A, Peleraux A, et al. Repression of cell cycle-related proteinsby oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006;5:2149-57
23. Jacobs S, McCully CL, Murphy RF, et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 2010;65:817-24
24. Levi F, Metzger G, Masarri C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000;38(1):1-21
25. Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 2012;13:125-37
26. Mani S, Manalo J, Bregman D. Novel combinations with oxaliplatin. Oncology (Williston Park) 2000;14:52-8
27. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012;307:1383-93
28. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94
29. Wang Q, You T, Yuan D, et al. Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther 2010;333:903-11
30. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20
31. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 2003;10:1663-82
32. Sorenson CM, Eastman A. Mechanism of cisdiamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988;48:4484-8
33. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 2010;7:543-66
34. Dmitriev OY. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B. Biochem Cell Biol 2011;89:138-47
35. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579-85
36. Wang And X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem 2007;7:19-34
37. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23
38. Zhu G, Myint M, Ang WH, et al. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Cancer Res 2012;72:790-800
39. Alberts DS. Clinical pharmacology of carboplatin. Semin Oncol 1990;17:6-8
40. Misset JL. Oxaliplatin in practice. Br J Cancer 1998;77:4-7
41. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002;29:21-33
42. Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999;43:1-7
43. Vaage J, Donovan D, Wipff E, et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999;80:134-7
44. Working PK, Newman MS, Sullivan T, et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998;46:155-65
45. Veal GJ, Griffin MJ, Price E, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001;84:1029-35
46. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-6
47. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-8
48. Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34:427-32
49. Seetharamu N, Kim E, Hochster H, et al. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res 2010;30:541-5
50. Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53:329-36
51. Schroeder A, Honen R, Turjeman K, et al. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 2009;137:63-8
52. Terkola R. Liposomal cisplatin: lipoplatin. EJOP 2007;1:15-20
53. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv 2012;2012:581363
54. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (lipoplatin) in mouse xenografts. Oncol Rep 2004;12:3-12
55. Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 2004;24:2193-200
56. Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am J Vet Res 2004;65:1474-8
57. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (lipoplatin): phase I study. Oncol Rep 2005;13:589-95
58. Stathopoulos GP, Rigatos SK, Stathopoulos J. Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study. Anticancer Res 2010;30:1317-21
59. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005;25:3031-9
60. Jehn CF, Boulikas T, Kourvetaris A, et al. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007;27:471-5
61. Farhat FS, Ibrahim K, Kattan J, et al. Preliminary results of phase II study of liposomal cisplatin-vinorelbine combination as first-line treatment in HER2/neu negative metastatic breast cancer (MBC). Clin Breast Cancer 2011;11:384-9
62. Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010;68:240-7
63. Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010;21:2227-32
64. De Oliveira MC, Fattal E, Couvreur P, et al. pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim Biophys Acta 1998;1372:301-10
65. Leite EA, Lana AM, Junior AD, et al. Acute toxicity study of cisplatin loaded long-circulating and pH-sensitive liposomes administered in mice. J Biomed Nanotechnol 2012;8:229-39
66. Araujo JG, Mota LG, Leite EA, et al. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice. Exp Biol Med (Maywood) 2011;236:808-15
67. Junior AD, Mota LG, Nunan EA, et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007;80:659-64
68. Woo J, Chiu GN, Karlsson G, et al. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm 2008;349:38-46
69. Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 2012;162:400-6
70. Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72(21):5566-75
71. Tippayamontri T, Kotb R, Paquette B, Sanche L. Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs 2011;29:1321-7
72. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 2006;26:1489-93
73. Liu XP, Geng DQ, Xu HX, Sui XH. The tissue distribution in mice and pharmacokinetics in rabbits of oxaliplatin liposome. J Liposome Res 2009;19:278-86
74. Zalba S, Navarro I, Troconiz IF, et al. Application of different methods to formulate PEG-liposomes of oxaliplatin: Evaluation in-vitro and in-vivo. Eur J Pharm Biopharm 2012;81:273-80
75. Abu Lila AS, Kizuki S, Doi Y, et al. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009;137:8-14
76. Abu Lila AS, Doi Y, Nakamura K, et al. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release 2010;142:167-73
77. Lohr JM, Haas SL, Bechstein WO, et al. CT4001 Study Group. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol 2012;5):1214-22
78. Maclean DS, Khokhar AR, Tyle P, Perez-Soler R. Intraliposomal chemical activation patterns of liposomal cis-bisneodecanoato-trans-R,R-1,2- diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent. J Microencapsul 2000;17:307-22
79. Perez-Soler R, Khokhar AR. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res 1992;52(22):6341-7
80. Perez-Soler R, Khokhar AR, Claringbold P, et al. Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-biscyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles. J Natl Cancer Inst 1986;77:1137-43
81. Perez-Soler R, Khokhar AR, Lopez-Berestein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles. Cancer Res 1987;47:6462-6
82. Lautersztain J, Perez-Soler R, Khokhar AR, et al. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyliminodiacetato-1,2- diaminocyclohexaneplatinum (II). Cancer Chemother Pharmacol 1986;18:93-7
83. Perez-Soler R, Khokhar AR, Hacker MP, Lopez-Berestein G. Toxicity and antitumor activity of cis-biscyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res 1986;46:6269-73
84. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 1988;22:223-7
85. Khokhar AR, al-Baker S, Krakoff IH, Perez-Soler R. Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother Pharmacol 1989;23:219-24
86. Vadiei K, Siddik ZH, Khokhar AR, et al. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992;30:365-9
87. Perez-Soler R, Shin DM, Siddik ZH, et al. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997;3:373-9
88. Verschraegen CF, Kumagai S, Davidson R, et al. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato (trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 2003;129:549-55
89. Dragovich T, Mendelson D, Kurtin S, et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 2006;58:759-64
90. Lu C, Perez-Soler R, Piperdi B, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005;23:3495-501
91. Seynhaeve AL, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007;67(19):9455-62
92. Pasquetto MV, Vecchia L, Covini D, et al. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34:611-28
93. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42(5):439-62
94. Koning GA, Morselt HW, Gorter A, et al. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases. Pharm Res 2001;18(9):1291-8
95. Koning GA, Kamps JA, Scherphof GL. Interference of macrophages with immunotargeting of liposomes. J Liposome Res 2002;12(1-2):107-19
96. Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 2008;346:143-50
97. Chaudhury A, Das S, Bunte RM, Chiu GN. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomedicine 2012;7:739-51
98. Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs 2009;18:1787-97
99. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009;5:33-42
100. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model. J Invest Dermatol 2003;120(3):476-82